Extremely encouraging are the results of clinical trials of a new treatment to treat diabetes mellitus, which will cause unnecessary daily intake of insulin by patients with injections. Diabetes mellitus is divided into two categories. Type 2 diabetes is a metabolic disorder characterized by high blood glucose values in the context of insulin resistance and relative insulin deficiency.
In contrast, type 1 diabetes mellitus is characterized by an absolute insulin deficiency due to the destruction of cells in the pancreas. Over the past 50 years, diabetes rates have grown significantly, along with obesity. Since 2010, about 285 million people have been affected. By comparison, in 1985 the patients amounted to 30 million.
Long-term complications due to high blood sugar may include the following conditions: heart disease, stroke, diabetic retinopathy, a condition affecting vision, kidney failure, etc. The overwhelming majority of diabetes patients have type 2 diabetes.
A team of researchers at the UMC Amsterdam University Hospital in the Netherlands has developed a new revolutionary method of treating Type 2 diabetes in order to improve the quality of life of patients and eliminate the inconvenience suffered by daily intake of insulin through injections.
In the small intestine there is a mucous membrane and scientists believe there is a relationship between membrane absorption of nutrients and insulin resistance. The Guardian newspaper reported that the researchers destroyed the mucous membrane in the small intestine and caused the development of a new one, managing to stabilize the blood sugar levels of people with type 2 diabetes.
The method is based on a tube at its end which has a small balloon. The tube is inserted into the patient through the mouth in the small intestine. The trial involved 50 patients with type 2 diabetes. The balloon was filled with hot water and the membrane was burned by the high temperature.
Within two weeks a new membrane developed which helped to improve patient health. Researchers presenting the test results at a large medical conference held in Vienna reported that one year after treatment, type 2 diabetes remained stable in 90% of the patients who underwent the treatment.